Key points are not available for this paper at this time.
We implemented a prospective study to evaluate platelet transfusion utilization, resource use, and costs in a tertiary care hospital over a 6-month period. All hospitalized patients receiving platelet transfusions between July and December 1996 were followed prospectively to determine platelet use and costs. Clinical and financial data were collected, evaluated, and compared to identify trends in resource utilization based on admitting service and platelet-refractory status. One thousand nine hundred forty-four platelet units were transfused to 245 hospitalized patients (50. 6% male, mean age 49 years) during the study period. The majority of platelet units transfused were single donor (N = 1, 460, 75%) and administered to bone marrow patients and patients with a hematological malignancy/disorder. Median hospitalization costs per admission were 27, 750, ranging from a high of 58, 729 for admission to the Bone Marrow Transplant service to 13, 856 per admission to the Internal Medicine/Other service. Patients were refractory to platelet transfusions during 21. 6% of hospitalizations. Hospital stays were longer (35. 0 days vs. 14. 4 days, P < 0. 001) and inpatient hospital costs (103, 956 vs. 37, 817, P < 0. 001) were more than two and a half times higher for patients refractory to platelet transfusions. Platelet utilization, resource use, and costs vary by admitting service. Refractoriness to platelet transfusion was associated with significantly greater costs and lengths of stay. Monitoring platelet transfusion practices, particularly for patients refractory to platelet transfusions, may be beneficial for limiting costs and improving efficacy.
Meehan et al. (Sat,) studied this question.